Inhibitory effects of antimicrobial agents against Fusarium species.

We investigated the inhibitory effects of antibacterial, biocidal, and antifungal agents against Fusarium spp. Seven Fusarium spp: four F. falciforme (Fusarium solani species complex), one Fusarium spp, one Fusarium spp. (Fusarium incarnatum-equiseti species complex), and one F. napiforme (Gibberella fujikuroi species complex), isolated from eyes with fungal keratitis were used in this study. Their susceptibility to antibacterial agents: flomoxef, imipenem, gatifloxacin, levofloxacin, moxifloxacin, gentamicin, tobramycin, and Tobracin® (contained 3,000 μg/ml of tobramycin and 25 μg/ml of benzalkonium chloride (BAK), a biocidal agent: BAK, and antifungal agents: amphotericin B, pimaricin (natamycin), fluconazole, itraconazole, miconazole, voriconazole, and micafungin, was determined by broth microdilution tests. The half-maximal inhibitory concentration (IC50), 100% inhibitory concentration (IC100), and minimum inhibitory concentration (MIC) against the Fusarium isolates were determined. BAK had the highest activity against the Fusarium spp. except for the antifungal agents. Three fluoroquinolones and two aminoglycosides had inhibitory effects against the Fusarium spp. at relatively high concentrations. Tobracin® had a higher inhibitory effect against Fusarium spp. than tobramycin alone. Amphotericin B had the highest inhibitory effect against the Fusarium spp, although it had different degrees of activity against each isolate. Our findings showed that fluoroquinolones, aminoglycosides, and BAK had some degree of inhibitory effect against the seven Fusarium isolates, although these agents had considerably lower effect than amphotericin B. However, the inhibitory effects of amphotericin B against the Fusarium spp. varied for the different isolates. Further studies for more effective medications against Fusarium, such as different combinations of antibacterial, biocidal, and antifungal agents are needed.

[1]  K. Kamei,et al.  Development of cycling probe-based real-time PCR system to detect Fusarium species and Fusarium solani species complex (FSSC). , 2014, International journal of medical microbiology : IJMM.

[2]  A. Galor,et al.  Current Thoughts in Fungal Keratitis: Diagnosis and Treatment , 2013, Current Fungal Infection Reports.

[3]  G. Satpathy,et al.  Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis. , 2013, Ophthalmology.

[4]  M. Srinivasan,et al.  The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. , 2013, JAMA ophthalmology.

[5]  Lu-tan Zhou,et al.  Antifungal effect of ophthalmic preservatives phenylmercuric nitrate and benzalkonium chloride on ocular pathogenic filamentous fungi. , 2013, Diagnostic microbiology and infectious disease.

[6]  A. Matoba.  Fungal Keratitis Responsive to Moxifloxacin Monotherapy , 2012, Cornea.

[7]  M. Ghannoum,et al.  Characterization of fusarium keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis. , 2012, Investigative ophthalmology & visual science.

[8]  Dong Cheol Lee,et al.  A Case of Fusarium Keratitis Treated with Moxifloxacin 0.5% Ophthalmic Solution , 2012 .

[9]  Dongqing Zhao,et al.  In Vitro Activity of Thimerosal against Ocular Pathogenic Fungi , 2009, Antimicrobial Agents and Chemotherapy.

[10]  M. Brandt,et al.  Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods. , 2008, Diagnostic microbiology and infectious disease.

[11]  T. Lietman,et al.  Activity of antibiotics against Fusarium and Aspergillus , 2008, British Journal of Ophthalmology.

[12]  Kerry O'Donnell,et al.  Molecular Phylogenetic Diversity, Multilocus Haplotype Nomenclature, and In Vitro Antifungal Resistance within the Fusarium solani Species Complex , 2008, Journal of Clinical Microbiology.

[13]  C. Gianni,et al.  Species Distribution and In Vitro Antifungal Susceptibility Patterns of 75 Clinical Isolates of Fusarium spp. from Northern Italy , 2008, Antimicrobial Agents and Chemotherapy.

[14]  E. Mellado,et al.  Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. , 2008, The Journal of antimicrobial chemotherapy.

[15]  J. Stockman.  Multistate Outbreak of Fusarium Keratitis Associated With Use of a Contact Lens Solution , 2008 .

[16]  D. Lam,et al.  A Case Series of Contact Lens-Associated Fusarium Keratitis in Hong Kong , 2007, Cornea.

[17]  Wuqaas M. Munir,et al.  Clinical Response of Contact Lens-Associated Fungal Keratitis to Topical Fluoroquinolone Therapy , 2007, Cornea.

[18]  D. Geiser,et al.  Phylogenetic Diversity and Microsphere Array-Based Genotyping of Human Pathogenic Fusaria, Including Isolates from the Multistate Contact Lens-Associated U.S. Keratitis Outbreaks of 2005 and 2006 , 2007, Journal of Clinical Microbiology.

[19]  K. Wannemuehler,et al.  Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. , 2006, JAMA.

[20]  T. Wong,et al.  An outbreak of Fusarium keratitis associated with contact lens wear in Singapore. , 2006, JAMA.

[21]  H. Flynn,et al.  In Vitro Antifungal Activity of the Fourth Generation Fluoroquinolones Against Candida Isolates from Human Ocular Infections , 2006, Ocular immunology and inflammation.

[22]  A. Mehta,et al.  Antibiotic inhibition of pectolytic and cellulolytic enzyme activity in twoFusarium species , 1993, Mycopathologia.

[23]  J. Rex,et al.  In Vitro Activities of Investigational Triazoles against Fusarium Species: Effects of Inoculum Size and Incubation Time on Broth Microdilution Susceptibility Test Results , 2002, Antimicrobial Agents and Chemotherapy.

[24]  W. Culbertson,et al.  Tobramycin-responsive Fusarium oxysporum keratitis. , 2000, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[25]  A. D. Russell,et al.  Antiseptics and Disinfectants: Activity, Action, and Resistance , 1999, Clinical Microbiology Reviews.

[26]  A. Lewin,et al.  Inhibition of RNA Synthesis as a Therapeutic Strategy against Aspergillus and Fusarium: Demonstration of In Vitro Synergy between Rifabutin and Amphotericin B , 1998, Antimicrobial Agents and Chemotherapy.

[27]  C. Clancy,et al.  The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. , 1998, The Journal of antimicrobial chemotherapy.

[28]  A. Dalhoff.  Pleiotropic actions of aminoglycosides. , 1987, Antibiotics and chemotherapy.

[29]  Natamycin approved--first U.S. drug for fungal keratitis. , 1978, FDA drug bulletin.

[30]  L. Wilson,et al.  Dematiaceous fungal keratitis. Clinical isolates and management. , 1975, The British journal of ophthalmology.